Nuri Company
Overview
Explore the profile of Nuri Company including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
53
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ruiz C, Pla M, Company N, Riudavets J, Nadal A
Plant Mol Biol
. 2015 Dec;
90(4-5):329-43.
PMID: 26687131
Cationic α-helical antimicrobial peptides such as BP100 are of increasing interest for developing novel phytosanitary or therapeutic agents and products with industrial applications. Biotechnological production of these peptides in plants...
2.
Company N, Nadal A, Ruiz C, Pla M
PLoS One
. 2014 Nov;
9(11):e109990.
PMID: 25387106
Synthetic linear antimicrobial peptides with cationic α-helical structures, such as BP100, have potent and specific activities against economically important plant pathogenic bacteria. They are also recognized as valuable therapeutics and...
3.
Company N, Nadal A, La Paz J, Martinez S, Rasche S, Schillberg S, et al.
Plant Biotechnol J
. 2013 Oct;
12(1):81-92.
PMID: 24102775
Synthetic linear antimicrobial peptides with cationic α-helical structures, such as BP100, are valuable as novel therapeutics and preservatives. However, they tend to be toxic when expressed at high levels as...
4.
Nadal A, Montero M, Company N, Badosa E, Messeguer J, Montesinos L, et al.
BMC Plant Biol
. 2012 Sep;
12:159.
PMID: 22947243
Background: The Biopeptide BP100 is a synthetic and strongly cationic α-helical undecapeptide with high, specific antibacterial activity against economically important plant-pathogenic bacteria, and very low toxicity. It was selected from...